Search results
Results from the WOW.Com Content Network
Benzodiazepine withdrawal syndrome (BZD withdrawal) is the cluster of signs and symptoms that may emerge when a person who has been taking benzodiazepines as prescribed develops a physical dependence on them and then reduces the dose or stops taking them without a safe taper schedule.
For example, in an MDMA ("ecstasy" and "molly") comedown, if the user experiences severe, persisting emotional distress, such as panic attacks, severe generalized anxiety, or insomnia following an MDMA session, a physician may prescribe a benzodiazepine (specifically, lorazepam) and/or sleep aid (e.g., zolpidem), to alleviate those effects.
Trifluoperazine is an effective antipsychotic for people with schizophrenia condition. [5] There is low-quality evidence that trifluoperazine increases the chance of being improved when compared to placebo when people are followed up for 19 weeks. [5]
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
Lurasidone, sold under the brand name Latuda among others, is an atypical antipsychotic medication used to treat schizophrenia and bipolar depression. [2] It is taken by mouth . Common side effects include sedation , indigestion , nausea , and insomnia .
In general, contraindications to antipsychotic switching are cases in which the risk of switching outweighs the potential benefit. Contraindications to antipsychotic switching include effective treatment of an acute psychotic episode, patients stable on a LAI antipsychotic with a history of poor adherence, and stable patients with a history of self-injurious behavior, violent behavior, or ...
There has been a study that suggests antipsychotics are associated with possible cortical reconfiguration and gray matter loss, [19] but correlational data also suggests patients who consume antipsychotics, like people with schizophrenia, tend to engage in unhealthy habits like smoking which may exacerbate gray matter loss.
Unlike many antipsychotics that are D 2 and 5-HT 2A receptor antagonists, cariprazine is a D 2 and D 3 partial agonist. It also has a higher affinity for D 3 receptors. The D 2 and D 3 receptors are important targets for the treatment of schizophrenia, because the overstimulation of dopamine receptors has been implicated as a possible cause of ...